1,363 results match your criteria Clinical Genitourinary Cancer [Journal]


How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects?

Clin Genitourin Cancer 2018 Dec 20. Epub 2018 Dec 20.

University of Calgary, Calgary, AB, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada. Electronic address:

Background: Androgen deprivation therapy (ADT) for prostate cancer has numerous side effects. Clinical guidelines for side effect management exist; however, these are not always integrated into routine practice. What remains undocumented and therefore the objective of this study, is to describe patients' willingness to employ established strategies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183072
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.006DOI Listing
December 2018
3 Reads
1.693 Impact Factor

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Jan 15. Epub 2019 Jan 15.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address:

Renal-cell carcinoma remains one of the elusive cancers that lacks a biomarker. It is the eighth most commonly diagnosed malignancy in the United States, and the incidence has slowly trended upward. In addition to the increase in newly diagnosed cases, the prevalence and overall survival of individuals with kidney cancer also has increased substantially. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.004DOI Listing
January 2019
1 Read

Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome?

Clin Genitourin Cancer 2019 Jan 10. Epub 2019 Jan 10.

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.002DOI Listing
January 2019

Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer.

Clin Genitourin Cancer 2019 Jan 9. Epub 2019 Jan 9.

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address:

Background: The aim of this study was to compare survival outcomes in patients with clinically node-positive muscle-invasive bladder cancer receiving induction chemotherapy (IC) followed by surgery and those who underwent upfront radical cystectomy (RC).

Patients And Methods: Outcomes were reviewed in patients with cT2-4N1-3M0 bladder cancer treated with IC followed by surgery or upfront RC between January 1995 and June 2017. Survival outcomes were analyzed using a propensity score matched cohort analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.001DOI Listing
January 2019
1 Read

Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.

Clin Genitourin Cancer 2018 Dec 21. Epub 2018 Dec 21.

Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Background: Prostate cancer with neuroendocrine differentiation (NEPCA) shares similarities in tumor biology with small-cell lung cancer. While immunotherapies were successfully tested in small-cell lung cancer, and programmed death ligand 1 (PD-L1) expression arises as an essential predictive biomarker, the local immune status in NEPCA is still poorly described.

Patients And Methods: Paraffin-embedded tissue samples of 39 patients (7 adenocarcinomas with neuroendocrine differentiation [ACA NED], 20 small-cell neuroendocrine carcinomas, 2 well-differentiated neuroendocrine tumors of NEPCA, and 10 adenocarcinoma liver metastases) were examined retrospectively by immunohistochemistry of chromogranin A (CGA), CD56, synaptophysin (SYN), CD3, and PD-L1. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183058
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.007DOI Listing
December 2018
3 Reads

Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.

Clin Genitourin Cancer 2019 Jan 4. Epub 2019 Jan 4.

Department of Medical Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.

Although tyrosine kinase inhibitors (TKIs) are widely used in the metastatic setting, they have shown more limited effectiveness in the adjuvant setting. Despite multiple clinical trials, there has been no improvement in overall survival (OS) with the use of these agents as adjuvant therapy, and conflicting data on disease-free survival (DFS). We carried out a meta-analysis of available phase III randomized clinical trials on adjuvant TKIs in clear-cell renal cell carcinoma (RCC). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193000
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.011DOI Listing
January 2019
4 Reads

Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial.

Clin Genitourin Cancer 2019 Jan 4. Epub 2019 Jan 4.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

Background: The objective of the study was to evaluate the outcomes of clinically localized prostate cancer treated with prostatectomy versus radiation therapy within the context of a prospective prostate cancer screening study.

Patients And Methods: Within the PLCO (Prostate, Lung, Colorectal, and Ovary) trial, patients who were diagnosed with clinically localized prostate cancer and subsequently received treatment with prostatectomy or radiation therapy (with or without hormonal treatment) were included. Univariate and multivariate Cox regression analyses were then performed to determine factors affecting overall and prostate cancer-specific survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.010DOI Listing
January 2019
1 Read

Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.

Clin Genitourin Cancer 2019 Jan 2. Epub 2019 Jan 2.

Kantonsspital Graubünden, Chur, Switzerland.

Background: There is evidence linking metformin to improved prostate cancer-related outcomes.

Patients And Methods: Twenty-five men with metastatic castration-resistant prostate cancer and prostate-specific antigen (PSA) progression while receiving treatment with abiraterone from 3 Swiss centers were included in this single-arm phase 2 trial between November 2013 and September 2016. Metformin was added to abiraterone continuously at 1000 mg twice daily in uninterrupted 4-week cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.009DOI Listing
January 2019

Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

Clin Genitourin Cancer 2019 Feb 4;17(1):38-45. Epub 2018 Oct 4.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. Electronic address:

Background: Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cisplatin-eligible patients who opt for bladder preservation warrants further evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.021DOI Listing
February 2019
1 Read

Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.

Clin Genitourin Cancer 2018 Dec 13. Epub 2018 Dec 13.

Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

Background: In the United States, the prostate cancer (PCa) incidence and death rate has been greater in non-Hispanic black (NHB) men than in non-Hispanic white (NHW) men and slightly lower in Hispanic men than in NHW men. We compared the sociodemographic and baseline prognostic factors at the diagnosis of PCa in different races/ethnicities at a large, academic center serving an ethnically diverse population.

Methods: The Montefiore Medical Center Cancer Registry was used to generate a comprehensive list of all patients with PCa diagnosed from 2004 to 2014. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183059
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.003DOI Listing
December 2018
10 Reads

Clinicopathologic and Genomic Factors Associated With Oncologic Outcome in Patients With Stage III to IV Chromophobe Renal Cell Carcinoma.

Clin Genitourin Cancer 2018 Dec 8. Epub 2018 Dec 8.

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Background: Chromophobe renal cell carcinoma (chRCC) is known as an indolent tumor; however, mortality still occurs. We sought to determine the clinicopathologic and genomic factors associated with aggressive chRCC.

Patients And Methods: Two different datasets were used to identify patients with clinical stage III and IV chRCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.002DOI Listing
December 2018
2 Reads

Metronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report.

Clin Genitourin Cancer 2018 Dec 19. Epub 2018 Dec 19.

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taiwan; School of Medicine, Chang Gung University, Taoyuan City, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.005DOI Listing
December 2018
1 Read

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

Clin Genitourin Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183078
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.004DOI Listing
December 2018
6 Reads

Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma.

Clin Genitourin Cancer 2018 Dec 7. Epub 2018 Dec 7.

Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan. Electronic address:

Background: Severe adverse events frequently occur in patients treated with pazopanib, necessitating dose reduction and discontinuation. However, information on the exposure-toxicity relationship is limited.

Patients And Methods: For this retrospective and observational clinical study, we examined 27 patients with renal cell carcinoma treated with pazopanib and enrolled between October 2014 and March 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.001DOI Listing
December 2018
2 Reads

Metastatic Urachus Neoplasia: A Case Report and Review of the Current Literature.

Clin Genitourin Cancer 2018 Dec 4. Epub 2018 Dec 4.

Australian National University Medical School, Canberra, Australia; Department of Oncology, The Canberra Hospital, Canberra, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.017DOI Listing
December 2018
1 Read
1.693 Impact Factor

Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.

Clin Genitourin Cancer 2018 Nov 22. Epub 2018 Nov 22.

Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX.

Background: Brain metastases (BM) pose a significant problem in patients with metastatic renal-cell carcinoma (mRCC). Local and systemic therapies including stereotactic radiosurgery (SRS) are rapidly evolving, necessitating reassessments of outcomes for modern patient management.

Patients And Methods: The mRCC patients with BM treated with SRS were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.006DOI Listing
November 2018
5 Reads
1.693 Impact Factor

Early Discharge After Radical Nephrectomy: An Analysis of Complications and Readmissions.

Clin Genitourin Cancer 2018 Dec 3. Epub 2018 Dec 3.

Center for Surgery and Health Economics, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

Introduction: Length of stay (LOS) is increasingly being viewed as a quality metric, and efforts to reduce LOS are present across most surgical subspecialties. However, data on whether reducing LOS is safe in patients who undergo radical nephrectomy (RN) are lacking. The purpose of this study was to assess whether early discharge after RN affects readmission rates and postdischarge complications using a national cohort of patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183036
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.11.016DOI Listing
December 2018
9 Reads

Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct Syndrome.

Clin Genitourin Cancer 2018 Dec 5. Epub 2018 Dec 5.

Department of Medical Oncology, Centre Hospitalier Lyon Sud, Institut de cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, France; UMR INSERM 1052, CNRS 5286, Centre de recherche en cancérologie de Lyon (CRCL), Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183077
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.11.019DOI Listing
December 2018
8 Reads

Male Breast Cancer Detected by Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis.

Clin Genitourin Cancer 2018 Dec 4. Epub 2018 Dec 4.

Metropolitan Nuclear Medicine, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.020DOI Listing
December 2018
2 Reads

Metastatic Lesion From Clear-cell Renal Carcinoma After 40 Years and a Review of the Literature.

Clin Genitourin Cancer 2018 Dec 3. Epub 2018 Dec 3.

Department of Orthopedics and Orthopedic Oncology, University of Padova, Padova, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183077
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.11.018DOI Listing
December 2018
10 Reads

Signal Transduction Peptide of Tissue Factor Phosphorylated at Ser258 and the Unphosphorylated STP in Urine Are Potential Biomarkers for Bladder Cancer.

Clin Genitourin Cancer 2018 Nov 17. Epub 2018 Nov 17.

Joint Centre for Cancer Studies, Hull York Medical School, Castle Hill Hospital, Cottingham, UK. Electronic address:

Background: Procoagulant activity attributed to tissue factor (TF, CD142) bound to lipid microvesicles has previously been shown to be elevated in urine of patients with various solid cancers. The phosphorylation of the C-terminal signal transduction peptide (STP) at Ser253 and Ser258 has been determined to be important for the formation of TF-microvesicles. The purpose of this work was to investigate the marker potential of the TF-STP domain in urine of patients with cancer using immunologic methods to quantitate unphosphorylated TF and TF phosphorylated at Ser253 and Ser258. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.005DOI Listing
November 2018
1 Read

High-Dose Chemotherapy in Relapsed or Refractory Metastatic Germ-Cell Cancer: The Scotland Experience.

Clin Genitourin Cancer 2018 Nov 17. Epub 2018 Nov 17.

Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, Scotland.

Purpose: To report outcomes from high-dose chemotherapy (HDCT) and autologous stem-cell transplantation (ASCT) for metastatic germ-cell cancer in Scotland.

Patients And Methods: All patients who underwent this treatment between the years 2001 and 2016 at the Beatson West of Scotland Cancer Centre in Glasgow were identified. Information regarding baseline patient and tumor characteristics, prognostic features, HDCT delivery, and survival outcomes were obtained retrospectively from patients' medical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.013DOI Listing
November 2018
1 Read

Capturing Renal Cell Carcinoma Recurrences When Asymptomatic Improves Patient Survival.

Clin Genitourin Cancer 2018 Nov 22. Epub 2018 Nov 22.

Division of Urology, Department of Surgery, Penn State College of Medicine, Hershey, PA.

Introduction: The purpose of this study was to explore whether the practice of postoperative renal cell carcinoma (RCC) surveillance affords a survival benefit by investigating whether detection of RCC recurrences in an asymptomatic versus symptomatic manner influences mortality.

Patients And Methods: We identified 737 patients who underwent partial or radical nephrectomy for M0 RCC between 1998 and 2016. Overall survival and disease-specific survival stratified by the type of recurrence detection (asymptomatic vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.009DOI Listing
November 2018
3 Reads

Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.

Clin Genitourin Cancer 2018 Nov 22. Epub 2018 Nov 22.

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Radium-223 therapy was registered in 2013 as a new life-prolonging therapeutic option for patients with symptomatic bone metastatic castration-resistant prostate cancer after the phase 3 ALSYMPCA study. Postregistration reports on the use of radium-223 in real-world populations demonstrate that appropriate selection of patients for radium-223 therapy is challenging. While primarily retrospective and post hoc studies identified prognostic variables associated with overall survival, validated predictive biomarkers are still lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.008DOI Listing
November 2018
1 Read

Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma.

Clin Genitourin Cancer 2018 Nov 17. Epub 2018 Nov 17.

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Background: There are no previous reports directly evaluating immunologic conditions in tumor microenvironment including both bladder cancer (BCa) and upper urinary tract carcinoma (UTUC). In this study, we aimed to clarify the difference of immunity status and its clinical significance depending on the tumor site in urothelial carcinoma.

Patients And Methods: Tumor tissue-infiltrating lymphocytes were extracted from 70 urothelial cancer patients who underwent surgical resection (52 cases of BCa and 18 cases of UTUC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.004DOI Listing
November 2018
1 Read

Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.

Clin Genitourin Cancer 2018 Nov 17. Epub 2018 Nov 17.

Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.

In patients with metastatic castration-resistant prostate cancer, bone is the most common site for metastases. Because of their osteoblastic character, these lesions are very suitable for treatment with bone-seeking radiopharmaceuticals (RPs). Nowadays, radium-223-chloride is the only RP with a proven benefit in overall survival, whereas the β-emitting RPs are used for pain palliation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183009
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.11.014DOI Listing
November 2018
9 Reads

Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2018 Nov 22. Epub 2018 Nov 22.

Department of Oncology, Mater Salutis Hospital, Legnago, Italy.

Purpose: To assess the pharmacologic costs of second-line treatments for metastatic renal-cell cancer (mRCC).

Methods: The present evaluation was restricted to pivotal phase 3 randomized controlled trials in second-line for mRCC. We calculated the pharmacologic costs necessary to get the benefit in progression-free survival and overall survival (OS) for each trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.010DOI Listing
November 2018
1 Read

Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.

Clin Genitourin Cancer 2018 Nov 13. Epub 2018 Nov 13.

Department of Urology, Peking University First Hospital, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. Electronic address:

Background: Programmed death ligand-1 (PD-L1) is a potential predictive biomarker for immunotherapy in several malignancies. However, the expression level and clinical significance of PD-L1 in von Hippel-Lindau (VHL)-associated hereditary clear-cell renal cell carcinoma (ccRCC) remain unclear.

Patients And Methods: Surgical specimens were recruited from 129 patients with sporadic ccRCC and 26 patients with VHL-associated hereditary ccRCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.001DOI Listing
November 2018
2 Reads

Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.

Clin Genitourin Cancer 2018 Dec 5. Epub 2018 Dec 5.

Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. Electronic address:

Background: Brain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized. In particular, outcomes after adjusting for systemic therapy administration and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors are not well-known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.007DOI Listing
December 2018
3 Reads
1.693 Impact Factor

Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Feb 29;17(1):e1-e11. Epub 2018 Sep 29.

Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.

Background: Previous studies have revealed that higher exposure of axitinib leads to better prognosis in metastatic renal-cell carcinoma. We thus assessed individualized dosing of axitinib on the basis of the first-dose area under the concentration-time curve from 0 to 12 hours (AUC) for sunitinib-pretreated metastatic renal-cell carcinoma patients.

Patients And Methods: In this prospective single-arm trial, the starting dose of axitinib was 5 mg twice daily. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.015DOI Listing
February 2019
1 Read

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.

Clin Genitourin Cancer 2018 Aug 11. Epub 2018 Aug 11.

Department of Urology, Ludwig-Maximilians University, Munich, Germany. Electronic address:

Objective: To systematically assessed the diagnostic performance of contrast-enhanced computed tomography (CT) compared to other imaging modalities for diagnosing and staging renal-cell carcinoma in adults.

Methods: A comprehensive literature search was conducted through various electronic databases. Data from the selected studies were extracted and pooled, and median sensitivity and specificity were calculated wherever possible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.07.024DOI Listing
August 2018
1 Read

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.

Clin Genitourin Cancer 2018 Nov 16. Epub 2018 Nov 16.

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Inserm UMR1162 Génomique Fonctionnelle des Tumeurs Solides, Université Paris-5 René Descartes, Paris, France. Electronic address:

Background: There are no validated markers that predict response or resistance in patients with metastatic clear-cell renal cell carcinoma (mccRCC) treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors such as sunitinib and pazopanib. Recently, single nucleotide polymorphism (SNP) rs2981582 in Fibroblast Growth Factor Receptor 2 (FGFR2) was found to be associated with clinical outcome in patients with mccRCC treated with pazopanib and sunitinib. We aimed to validate these findings in patients treated with sunitinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.002DOI Listing
November 2018
1 Read

More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder.

Clin Genitourin Cancer 2018 Nov 17. Epub 2018 Nov 17.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.

Background: Radical cystectomy (RC) may occasionally be performed in individuals with metastatic urothelial carcinoma of the bladder (mUCB). However, the role of lymph node dissection (LND) for such cases is unknown. Thus, we tested the effect of RC on cancer-specific mortality (CSM) and overall mortality in mUCB patients and the effect of LND and its extent on CSM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.003DOI Listing
November 2018
2 Reads

Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?

Clin Genitourin Cancer 2018 Oct 23. Epub 2018 Oct 23.

Department of Urology, Istituto Europeo di Oncologia, Milan, Italy; Università degli Studi di Milano, Milan, Italy; Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy.

Purpose: To understand the multiparametric magnetic resonance imaging (mpMRI) interreader agreement between radiologists of peripheral and academic centers and the possibility to avoid prostate biopsies according to magnetic resonance imaging second opinion.

Patients And Methods: This prospective observational study enrolled 266 patients submitted to mpMRI at nonacademic centers for cancer detection or at active surveillance begin. Images obtained were reviewed by 2 unblinded radiologists with 8 and 5 years' experience on mpMRI, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.006DOI Listing
October 2018
1 Read

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.

Clin Genitourin Cancer 2019 Feb 7;17(1):e227-e234. Epub 2018 Nov 7.

Department of Pharmacy, University Hospital, Besançon, France; INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, University Bourgogne Franche-Comté, Besançon, France. Electronic address:

Background: Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse. The purpose of this retrospective study was to evaluate cost of illness for 224 patients with mccRCC included in the cohort published by Thiery-Vuillemin et al (Factors influencing overall survival for patients with metastatic clear-cell renal cell-carcinoma in daily practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.016DOI Listing
February 2019
2 Reads

Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer.

Clin Genitourin Cancer 2019 Feb 23;17(1):e176-e183. Epub 2018 Oct 23.

Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Testicular germ cell tumors (TGCTs) represent the most common solid tumors among men aged 15 to 34 years. Fortunately, recent advances have made testicular cancer a highly curable disease. Despite the high cure rates, there are still several areas in testis cancer care where treatment decisions are controversial and guided only with clinical factors and historic serum tumor markers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183058
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.10.007DOI Listing
February 2019
8 Reads

Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.

Clin Genitourin Cancer 2019 Feb 4;17(1):23-31.e3. Epub 2018 Oct 4.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:

Introduction: There are limited randomized data comparing radical cystectomy (RC) with bladder-sparing tri-modality therapy (TMT) in the treatment of muscle-invasive bladder cancer (MIBC). Both strategies are thought to have similar survival outcomes with different morbidity profiles. We compare the effectiveness of TMT and RC using decision-analytic modeling and the endpoint of quality-adjusted life years (QALYs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.023DOI Listing
February 2019
3 Reads

Evaluation of Prostate Cancer Stage Groups Updated in the 8th Edition of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging Manual.

Clin Genitourin Cancer 2019 Feb 1;17(1):e221-e226. Epub 2018 Nov 1.

Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Urology, Seoul National University College of Medicine, Seoul, Korea. Electronic address:

Introduction: The American Joint Committee on Cancer (AJCC) tumor, node, metastasis classification system (TNM) staging manual has been updated and provides more specified stage grouping for prostate cancer (PCa). We aimed to validate the updated AJCC stage groups for PCa using a radical prostatectomy (RP) cohort.

Patients And Methods: We analyzed the data of 3032 patients previously treated with RP for localized PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.015DOI Listing
February 2019
14 Reads

Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?

Clin Genitourin Cancer 2019 Feb 29;17(1):e209-e215. Epub 2018 Oct 29.

Department of Urology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY. Electronic address:

Purpose: To determine a subset of women who could undergo ovary-sparing radical cystectomy (OSRC) for bladder cancer without compromising oncologic safety.

Patients And Methods: A retrospective review was performed of 164 consecutive women who underwent cystectomy at a single tertiary-care center from 1997 to 2018. Clinicopathologic and preoperative radiographic data were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.009DOI Listing
February 2019
2 Reads

Racial and Ethnic Disparities in Renal Cell Carcinoma: An Analysis of Clinical Characteristics.

Clin Genitourin Cancer 2019 Feb 27;17(1):e195-e202. Epub 2018 Oct 27.

Division of Urology, Department of Surgery, University of Arizona, Tucson, AZ.

Background: Racial/ethnic minority groups, including Hispanic Americans (HAs) and Native Americans (NAs), have a heavier burden of kidney cancer than European Americans (EAs). We investigated variations in clinical characteristics of HA and NA patients with renal cell carcinoma (RCC) who were previously underrepresented.

Materials And Methods: Clinical records of 294 patients with RCC (151 EAs, 95 HAs, 22 NAs, and 26 others) without prior diagnosis of cancer were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348034PMC
February 2019
15 Reads

Unravelling Adrenal Oncocytic Neoplasm.

Clin Genitourin Cancer 2019 Feb 26;17(1):e216-e220. Epub 2018 Oct 26.

Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Oncocytic neoplasms are rare tumors arising in the adrenal glands and usually considered as nonfunctional and benign. We report 4 cases of adrenal oncocytic neoplasm. The paucity of literature describing this entity increases the chance for misdiagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.011DOI Listing
February 2019
1 Read

Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer.

Clin Genitourin Cancer 2019 Feb 29;17(1):e184-e186. Epub 2018 Oct 29.

Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183074
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.10.014DOI Listing
February 2019
16 Reads
1.693 Impact Factor

A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer.

Clin Genitourin Cancer 2019 Feb 27;17(1):e203-e208. Epub 2018 Oct 27.

S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.

Background: There is a lack of real-world data regarding the treatment outcomes of chemohormonal therapy versus hormonal therapy alone in Chinese men with metastatic hormone-sensitive prostate cancer.

Patients And Methods: We conducted a territory-wide, multicenter, age- and prostate-specific antigen (PSA)-matched cohort study comparing chemohormonal therapy and hormonal therapy alone in Chinese men with metastatic hormone-sensitive prostate cancer. Patient and disease characteristics were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.010DOI Listing
February 2019
13 Reads

Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.

Clin Genitourin Cancer 2019 Feb 26;17(1):e187-e194. Epub 2018 Oct 26.

Medical Oncology Unit 1, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.

Background: Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.

Patients And Methods: We conducted a multicenter retrospective analysis in the Triveneto region of Italy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183055
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.10.013DOI Listing
February 2019
8 Reads

Pathologic Nodal Involvement in Patients With Penile Cancer With Cavernosal Versus Spongiosal Involvement.

Clin Genitourin Cancer 2019 Feb 13;17(1):e156-e161. Epub 2018 Oct 13.

Department of Urology, University of Washington School of Medicine, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA.

Background: The American Joint Committee on Cancer recently proposed new TNM staging for penile cancer, with proposed T2 as spongiosal invasion and T3 as cavernosal invasion. We sought to validate the proposed staging system for predicting pathologic nodal involvement using the National Cancer Data Base.

Patients And Methods: Invasive penile cancer cases from 2010 to 2012 were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.10.004DOI Listing
February 2019
7 Reads

Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Feb 23;17(1):e167-e175. Epub 2018 Oct 23.

Institute of Pathology, University Hospital Bonn, Bonn, Germany. Electronic address:

Background: Karyopherin α2 (KPNA2) is involved in the nucleocytoplasmic transport system and is functionally involved in the pathogenesis of various solid tumors by the translocation of cancer associated cargo proteins. However, the role of KPNA2 in renal-cell carcinoma (RCC) is still unknown. The aim of the present study was to investigate the protein expression of KPNA2 in cancerous and healthy renal tissues to evaluate its prognostic value in RCC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183042
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.10.008DOI Listing
February 2019
11 Reads

Outcomes in Organ Transplant Recipients With Prostate Cancer Treated With Radiotherapy.

Clin Genitourin Cancer 2019 Feb 18;17(1):e162-e166. Epub 2018 Oct 18.

Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH. Electronic address:

Background: Few data exist in the literature regarding outcomes of men with prostate cancer (CaP) who are receiving immunosuppression from prior organ transplantation. The aim of this study was to evaluate biochemical disease-free survival, distant metastasis-free survival, overall survival, and toxicity in patients with organ transplants who were later treated with definitive radiotherapy for CaP.

Patients And Methods: Our institutional CaP registry was reviewed to identify patients who had undergone an organ transplantation before CaP diagnosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183031
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.10.005DOI Listing
February 2019
10 Reads
1.693 Impact Factor